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Objectives
Transmission of drug-resistant HIV-1 has decreased in the UK since the early 2000s. This analysis reports
recent trends and characteristics of transmitted drug resistance (TDR) in the UK from 2010 to 2013.
Methods
Resistance tests conducted in antiretroviral treatment (ART)-na€ıve individuals between 2010 and
2013 were analysed for the presence of transmitted drug resistance mutations (TDRMs), defined as
any mutations from a modified 2009 World Health Organization surveillance list, or a modified
2013 International Antiviral Society-USA list for integrase tests. Logistic regression was used to
examine associations between demographics and the prevalence of TDRMs.
Results
TDRMs were observed in 1223 (7.5%) of 16 425 individuals; prevalence declined from 8.1% in 2010 to
6.6% in 2013 (P = 0.02). The prevalence of TDRMs was higher amongmen who have sex with men
(MSM) compared with heterosexual men and women (8.7% versus 6.4%, respectively) with a trend for
decreasing TDRMs amongMSM (P = 0.008) driven by a reduction in nucleoside reverse transcriptase
inhibitor (NRTI)-related mutations. The most frequently detected TDRMs were K103N (2.2%), T215
revertants (1.6%), M41L (0.9%) and L90M (0.7%). Predicted phenotypic resistance to first-line ART was
highest to the nonnucleoside reverse transcriptase inhibitors (NNRTIs) rilpivirine and efavirenz (6.2%
and 3.4%, respectively) but minimal to NRTIs, including tenofovir, and protease inhibitors (PIs). No
major integrase TDRMs were detected among 101 individuals tested while ART-na€ıve.
Conclusions
We observed a decrease in TDRMs in recent years. However, this was confined to the MSM population
and rates remained stable in those with heterosexually acquired HIV infection. Resistance to currently
recommended first-line ART, including integrase inhibitors, remained reassuringly low.
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Introduction
The majority of individuals initiating combination
antiretroviral treatment (ART) suppress virus replication
and are less likely to acquire drug resistance compared
with individuals who were exposed to older ART regi-
mens. However, approximately one-third of individuals
in the UK experiencing virological failure still have
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drug-resistant strains of HIV [1]. Onward transmission of
drug-resistant HIV can have an adverse effect on the
success of first-line treatment and may negatively
impact an individual’s prognosis [2]. National guidelines
in the UK [3] and many other European countries [4]
recommend that newly diagnosed individuals have a
resistance test to detect transmitted drug resistance
(TDR) and help selection of a fully active first-line treat-
ment regimen.
Surveillance of TDR in the UK has monitored the
impact of improved ART regimens and resistance testing
guidelines over time. Previous work reported a decrease
in the prevalence of TDR between 2001 and 2007 [5,6].
The prevalence of TDR in individuals with a subtype B
infection was higher than in those with non-B infec-
tions between 2001 and 2006, reflecting long-standing
free access to ART in the UK and limited availability
of ART in countries where non-B infections were prob-
ably acquired [5]. The prevalence of TDR in individuals
with a subtype B infection increased slightly between
2007 and 2009, driven by an increase in resistance to
the nucleoside reverse transcriptase inhibitor (NRTI)
drug class, leading to the hypothesis that onward trans-
mission of persistent thymidine analogue mutations
(TAMs) among undiagnosed men who have sex with
men (MSM) may keep levels of TDR stable in this pop-
ulation [6].
The European SPREAD. collaborative study reported a
similar pattern of a higher prevalence of TDR among
MSM compared with individuals who acquired their
infection heterosexually between 2002 and 2007 [7].
Other studies in high-income countries have reported
comparable rates of TDR; the European CHAIN collabora-
tion reported a prevalence of 9.5% between 1998 and
2008 [2], while a prevalence of 15% was reported in a US
study conducted between 1999 and 2011 [8].
Of increasing interest in recent years is the surveillance
of TDR to integrase inhibitors, a relatively new drug class
approved for use in HIV treatment in Europe in 2008.
The integrase inhibitors raltegravir, dolutegravir and
elvitegravir are increasingly likely to be used as first-line
ART in combination with two NRTIs. Other than a small
number of isolated case reports [9–11], studies have failed
to detect transmitted major integrase mutations [as
defined by the International Antiviral Society (IAS)-USA
2013 list [12]] in ART-na€ıve individuals [13–15].
Recently, the French PRIMO cohort study detected iso-
lated E157Q mutations in 1.5% of baseline samples [16].
The objective of this report was to examine the recent
prevalence, patterns and predictive factors of TDR among
ART-na€ıve persons living with diagnosed HIV infection
in the UK.
Methods
The UK HIV Drug Resistance Database (UK HDRD) collects
information from all National Health Service and Public
Heath England (PHE) virology laboratories performing
resistance tests as part of routine clinical care in the UK.
Nucleotide sequences of the protease and reverse tran-
scriptase and integrase genes are collected. Resistance
data are linked to demographic and clinical patient data
held in the UK Collaborative HIV Cohort study (UK CHIC)
database [17] and the national HIV/AIDS Reporting Sys-
tem (HARS) database held at PHE [18]. Eighty-three per
cent of resistance tests are successfully linked to one or
both sources.
Resistance testing of polymerase (pol) (protease and
reverse transcriptase genes) started in the UK in 1998, but
testing of ART-na€ıve individuals only became widespread
from 2005 following the release of British HIV Associa-
tion (BHIVA) guidelines recommending routine monitor-
ing of transmitted resistance in this population [3].
Sequencing of the integrase gene was first performed in
the UK in 2007 but to date only a small number of inte-
grase sequences have been reported from ART-na€ıve indi-
viduals. Findings in the pol and integrase genes are
described separately in this report. We selected the first
sequence per individual aged 15 years or over who had
not yet received ART at the time of sampling. Individuals
infected via mother-to-child transmission were excluded.
In this report, the term ‘transmitted drug resistance
mutations’ (TDRMs) is used to describe (a) for pol, the
presence of one or more mutations from the World Health
Organisation (WHO) 2009 surveillance list [19] with the
addition of E138K, a mutation known to cause resistance
to the second-generation nonnucleoside reverse transcrip-
tase inhibitor (NNRTI) rilpivirine, and all changes at codon
T215 as they are likely to be ancestrally related to T215F
or Y mutations [20]; (b) for integrase, the presence of
mutations from the IAS-USA 2013 list or accessory muta-
tions reported by the Stanford HIVdb algorithm v7.0 (HIV
Drug Resistance Database, Stanford University, Stanford,
CA). HIV-1 subtypes were determined using the REGA v3.0
genotyping tool (REGA Institute, Katholieke Universiteit
Leuven, Belgium). Predicted phenotypic resistance to ART
drugs currently recommended (preferred or alternative)
for first-line treatment of HIV infection in the UK [21]
was examined using the Stanford HIVdb algorithm v7.0.
Scores of low-level, intermediate or high-level resistance
were used to predict phenotypic resistance.
Univariate and multivariate logistic regression was
used to examine the association between demographic
and clinical factors and the prevalence of TDRMs. Demo-
graphic and clinical factors included in logistic regression
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models were: year of resistance test, transmission group,
ethnicity, age at diagnosis, region of treatment centre and
baseline CD4 T-cell count and HIV-1 viral load. Recent
Infection Testing Algorithm (RITA) avidity score was not
included in multivariate analysis given the close relation-
ship to baseline CD4 cell count and the availability of
more CD4 data. Viral subtype was not included as a sepa-
rate variable in either the univariate or multivariate anal-
yses because of the close association with ethnicity and
transmission group. Where demographic information was
missing, an unknown category was created to allow indi-
viduals to be included in multivariate analyses. A priori,
an interaction between year of resistance test and trans-
mission group was added to the adjusted model. Wald
tests were used to assess the effect of demographic factors
on the prevalence of TDRMs in the adjusted model. Indi-
viduals were defined as being recently infected when this
was confirmed with a RITA avidity score <80% and their
first resistance test was within 3 months of HIV diagno-
sis. The closest CD4 cell count and HIV-1 viral load mea-
sured within the year before or the 6 months after the
resistance test and before receiving ART were included in
analyses.
Analyses of time trends of TDRMs in pol are presented
from 2005 onwards to provide contextual data for recent
years (2010-2013), which are the focus of the report.
More detailed analyses of predicted phenotypic resistance
and predictors of TDRMs are limited to 2010-2013 to be
most relevant to contemporary clinical practice. Data on
TDRMs conferring resistance to integrase inhibitors cover
the period 2007 to 2013.
All analyses were carried out using STATA statistical
software version 13.0 (StataCorp LP, College Station, TX,
USA).
Results
A total of 40 549 individuals were tested for TDRMs (pol)
while ART-na€ıve between 2005 and 2013 (Table 1). Of
the 16 425 individuals who were tested in recent years
(2010–2013 inclusive), 66.5% were male and 49.7% of
white ethnicity. MSM comprised 45.9% of individuals,
with 39.4% acquiring their infection heterosexually. Med-
ian age at HIV diagnosis in recent years was 35 years [in-
terquartile range (IQR) 28–44 years]. Almost half of all
samples (45.6%) came from treatment centres in London,
followed by 19.5% from the Midlands and East England
region. Median CD4 cell count at the time of the resis-
tance test was 350 cells/mL (IQR 175–530 cells/lL). As
expected, the median CD4 cell count was higher in those
with a recent infection confirmed by a RITA assay:
546 cells/lL (1098 individuals) compared with 305 cells/
lL (4864 individuals) in nonrecent infections. The median
viral load at the time of the resistance test was 4.76 log10
HIV-1 RNA copies/mL (IQR 4.12–5.31 copies/mL). The
median time from HIV diagnosis to first resistance test
was 9 days. Subtype B viruses were the most commonly
detected (49.2%), followed by subtype C (21.7%), subtype
CRF02_AG (7.0%) and subtype A (5.8%). Only 16.0% of
heterosexual men and women were infected with subtype
B virus, while 42.6% had subtype C infection. Conversely,
almost 80% of MSM had subtype B virus and only 3.5%
subtype C. Demographic characteristics of ART-na€ıve
individuals tested for drug resistance in recent years were
comparable to those of individuals newly diagnosed with
HIV infection in the UK between 2010 and 2013 [22],
suggesting that our cohort is broadly representative of
this population in the UK.
The prevalence of TDRMs has declined over time, from
9.3% in 2005 to 6.6% in 2013 (test for trend P = 0.02)
(Fig. 1). As reported previously, the rate stabilized
between 2008 and 2010, but has declined in recent years
from 8.1% in 2010 to 6.6% in 2013 (test for trend
P = 0.02). This recent decline was driven by a decrease in
the prevalence of observed TDRMs in MSM (9.8% in
2010 to 7.5% in 2013; test for trend P = 0.008), while
the prevalence of TDRMs in heterosexual men and
women has remained stable in recent years (6.7% in 2010
and 6.2% in 2013; test for trend P = 0.56). The decrease
in observed TDRMs in MSM was driven by a reduction in
the prevalence of TDRMs conferring resistance to the
NRTI drug class (from 5.2% in 2010 to 3.7% in 2013; test
for trend P = 0.01), while the prevalence of TDRMs con-
ferring resistance to NNRTIs and protease inhibitors (PIs)
was unchanged over the 4 years (test for trend P = 0.63
for NNRTIs; P = 0.12 for PIs).
Further analysis of individuals tested between 2010
and 2013 revealed that, of the 1233 (7.5%) individuals
with one or more resistance mutations, 6.5% had resis-
tance to a single drug class, 0.9% had dual drug class
resistance and 0.1% had triple drug class resistance
(Table 2). Overall, 3.5% had TDRMs conferring resistance
to drugs from the NRTI class, 3.3% to the NNRTI class
and 1.7% to the PI drug class. The most frequently
detected mutations were T215 revertants (not F/Y) (268;
1.6%) and other TAMs [M41L (141; 0.9%) and K219Q/N
(104; 0.6%)] conferring resistance to the NRTI drug class;
K103N (354; 2.2%) and Y181C (66; 0.4%) conferring
resistance to the NNRTI drug class, and L90M (111; 0.7%)
and M46L (48; 0.3%) conferring resistance to the PI drug
class. Despite TAMs remaining the most commonly
detected NRTI resistance mutations, their prevalence has
been decreasing in recent years, from 4.5% in 2010 to
3.1% in 2013 (test for trend P = 0.001). K65R was only
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detected in 10 (0.06%) individuals tested between 2010
and 2013.
Table 3 shows a comparison between the prevalence of
TDRMs by drug class and predicted phenotypic resistance
to currently recommended first-line ART in the UK. Very
little relevant resistance was observed to currently recom-
mended first-line NRTIs or PIs: 1.2% and 0.9%, respec-
tively. In particular, the frequently detected TAMs are no
longer of direct clinical relevance in light of the replace-
ment of zidovudine by tenofovir in first-line therapy. A
Table 1 Demographic and clinical patient characteristics, 2005–2013
Patient characteristics
Year of resistance test
Year of HIV diagnosis
2005–2009 2010–2013 2010–2013*
Total n 24 124 16 425 24 828
Sex
Male 16050 (66.5) 10917 (66.5) 17769 (71.6)
Female 7133 (29.6) 3820 (23.3) 7059 (28.4)
Unknown 1941 (8) 1688 (10.3) 0
Transmission group
MSM 10057 (41.7) 7533 (45.9) 11678 (47.0)
Heterosexual male 4045 (16.8) 2833 (17.2) 4540 (18.3)
Heterosexual female 6833 (28.3) 3635 (22.1) 6119 (24.6)
IDU 465 (1.9) 298 (1.8) 530 (2.1)
Other 642 (2.7) 125 (0.8) 506 (2.0)
Unknown 2082 (8.6) 2001 (12.2) 1455 (5.9)
Ethnicity
White 11361 (47.1) 8169 (49.7) 13222 (53.3)
Black African 7792 (32.3) 3932 (23.9) 6741 (27.2)
Black Caribbean 830 (3.4) 565 (3.4) 708 (2.9)
Asian 621 (2.6) 720 (4.4) 1219 (4.9)
Other 1529 (6.3) 1139 (6.9) 1772 (7.1)
Unknown 1991 (8.3) 1900 (11.6) 1166 (4.7)
Age at diagnosis (years)
[median (IQR)] 34 (28–41) 35 (28–44) 36 (29–45)
Region of treatment centre/diagnosis
London 11557 (47.9) 7493 (45.6) 10823 (43.6)
South England 2811 (11.7) 2175 (13.2) 3542 (14.3)
North England 3778 (15.7) 2237 (13.6) 3997 (16.1)
Midlands and East England 3638 (15.1) 3208 (19.5) 4370 (17.6)
Wales 497 (2.1) 441 (2.7) 562 (2.3)
Scotland 1316 (5.5) 435 (2.6) 1135 (4.6)
Northern Ireland 198 (0.8) 252 (1.5) 358 (1.4)
Other/unknown 329 (1.4) 184 (1.1) 41 (0.2)
Baseline CD4 count
<200 cells/mL 4935 (20.5) 3249 (19.8) 5557 (22.4)
200–349 cells/mL 3909 (16.2) 2508 (15.3) 4259 (17.2)
350–499 cells/mL 3353 (13.9) 2528 (15.4) 4541 (18.3)
≥500 cells/mL 4032 (16.7) 3342 (20.3) 6728 (27.1)
Unknown 7895 (32.7) 4798 (29.2) 3743 (15.1)
CD4 count (cells/mL) [median (IQR)] 320 (160–497) 350 (175–530) 371 (187–558)
Baseline VL
<4.0 log10 copies/mL 2579 (10.7) 1262 (7.7) –
4.0 to <5.0 log10 copies/mL 3833 (15.9) 2396 (14.6) –
≥5.0 log10 copies/mL 2659 (11) 2268 (13.8) –
Unknown 15053 (62.4) 10499 (63.9) –
VL [median (IQR)] 4.54 (3.91–5.11) 4.76 (4.13–5.31) –
Subtype
A 1364 (5.7) 957 (5.8) –
B 11761 (48.8) 8085 (49.2) –
C 6742 (27.9) 3557 (21.7) –
G 586 (2.4) 438 (2.7) –
CRF01_AE 587 (2.4) 560 (3.4) –
CRF02_AG 1324 (5.5) 1150 (7) –
Other 1760 (7.3) 1678 (10.2) –
Time from diagnosis to resistance test (days) [median (IQR)]) 19 (4–239) 9 (1–36) –
IDU, injecting drug use; IQR, interquartile range; MSM, men who have sex with men; VL, viral load.
Values are n (%), unless otherwise stated.
*Data from PHE HIV surveillance data tables 2015 (https://www.gov.uk/government/statistics/hiv-data-tables) [22].
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higher incidence of predicted phenotypic resistance was
seen to first-line NNRTIs, with 8.2% of individuals having
predicted low-, intermediate- or high-level resistance to
current drugs in this class; 6.2% of individuals had pre-
dicted resistance to rilpivirine and 3.4% to efavirenz
(Fig. 2). Resistance to rilpivirine was largely low-level
resistance and probably a consequence of cross-resistance
to other NNRTIs, given the limited use of the drug in this
period.
The results of a multivariate logistic regression model
of potential predictive factors for TDRMs are shown in
Table 4. Although a test for interaction between year of
resistance test and transmission group did not reach con-
ventional statistical significance (P = 0.65), the interac-
tion term was retained because of the strong clinical
plausibility of this effect. In an additional model which
excluded this interaction term, the overall odds ratios
(ORs) for heterosexual men and heterosexual women ver-
sus MSM were 0.78 [95% confidence interval (CI) 0.64–
0.95] and 0.79 (95% CI 0.65–0.97), respectively. The only
significant predictor of TDRMs was geographical region
of attending treatment centre in the UK. Compared with
individuals attending London clinics, the odds of having
detectable TDRMs was lower in individuals attending
treatment centres in Northern Ireland, Wales, the Mid-
lands and East of England and the South of England
(52%, 49%, 40% and 20% lower, respectively). This asso-
ciation persisted in a sensitivity analysis limited to indi-
viduals with subtype B infection (P < 0.001). Neither
baseline CD4 cell count nor recency of infection defined
by RITA was associated with risk of TDRMs.
Of the integrase tests reported to the UKHDRD, 101
were performed in ART-na€ıve individuals between
Fig. 1 Prevalence of transmitted drug resistance mutations (TDRMs) by transmission group, 20052013.
MSM, men who have sex with men.
Table 2 Transmitted drug resistance mutations (TDRMs) by drug
class, 2010–2013
TDRMs by drug class n %
Any 1233 7.5
Single
NRTI only 425 2.6
NNRTI only 405 2.5
PI only 241 1.5
Dual
NRTI + NNRTI 121 0.7
NRTI + PI 17 0.1
NNRTI + PI 11 0.1
Triple
NRTI + NNRTI + PI 13 0.1
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
Table 3 Comparison of transmitted drug resistance mutations
(TDRMs) and predicted phenotypic resistance (Stanford scores) by
drug class, 2010–2013
ART drug
class
Surveillance
mutations
Predicted phenotypic resistance to currently
recommended first-line ART
% any
TDRM
% any low
level/intermediate/
high level
% any
intermediate/
high level
% any
high level
Any class 7.5 9.6 3.9 2.8
NRTI 3.5 1.2 0.8 0.6
NNRTI 3.3 8.2 3.5 2.6
PI 1.7 0.9 0.2 0.1
ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibi-
tor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease
inhibitor.
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January 2007 and December 2013. No major mutations
were identified in these 101 individuals. Six individuals
had minor or accessory mutations: one had L74M, two
had V151I and three had E157Q. In isolation, these muta-
tions are not reported to affect susceptibility to integrase
inhibitors with the exception of E157Q, which confers
low-level resistance to raltegravir and elvitegravir.
Discussion
Analysis of TDR in the ART-na€ıve UK population has
revealed a trend for decreasing prevalence of TDRMs
from 2005 to 2013, with 7.5% of individuals tested in
recent years (2010–2013) having detectable TDRM. Other
European cohort studies have also recently reported
temporal trends for decreasing TDR and clinically rele-
vant resistance to first-line treatments, including Span-
ish cohorts [23,24] and the PRIMO cohort in France
[16].
In the UK, the prevalence of TDRMs remains higher in
MSM than in heterosexuals, consistent with other studies
in high-income countries [16,24,25]. This difference has
been consistently reported in the UK [5] and can be
attributed to historical patterns of HIV acquisition. While
most MSM diagnosed in the UK have acquired their
infection in the UK, where access to treatment has been
free for decades, most heterosexuals historically acquired
HIV abroad, where resistant HIV was essentially absent as
a consequence of poor availability of ART [5]. However,
our analyses reveal that the difference in the prevalence
of TDRMs between these groups of individuals is narrow-
ing as different temporal patterns continue to be seen in
the two populations. As the proportion of heterosexual
infections acquired in the UK has increased from 36% in
2005 to 59% in 2013 [22], the prevalence of TDRMs in
heterosexual men and women has increased since 2006
and now appears to have stabilized between 2010 and
2013. In contrast, there has been a significant decrease in
detectable TDRMs among MSM, driven by declining resis-
tance to the NRTI drug class. Resistance to NRTIs is
higher in this group particularly as a consequence of his-
torical exposure to the thymidine analogues stavudine
and zidovudine, with mutations selected by these drugs
known to persist for long periods of time [26] and to be
onwardly transmitted from ART-na€ıve individuals [27].
This report found a decline in these mutations among
MSM in recent years, which suggests that they confer a
slight fitness disadvantage, and a continued decline in
their frequency is anticipated.
The prevalence of TDRMs in recent years, 7.5%, is a lit-
tle lower than has been reported by other European
cohort studies for the years since 2010 [16,23,24,28,29].
The incidence of dual or triple class resistance in ART-
na€ıve individuals is reassuringly very low. The TDRMs
detected have a minimal effect at a population level on
currently recommended first-line treatment options in the
UK, with predicted phenotypic resistance to individual PIs
and NRTIs generally being <1%. In contrast, the preva-
lence of predicted NNRTI resistance was higher; 6.2% and
3.4% of individuals had resistance to rilpivirine and efa-
virenz, respectively. Resistance testing prior to ART initi-
ation is therefore particularly useful if patients are to be
started on an NNRTI-containing first-line regimen to
ensure that the virus is fully susceptible to the chosen
third agent. The K65R mutation, which confers resistance
to tenofovir, was rarely detected as a transmitted mutation,
supporting previous work by our group suggesting that
this should not affect the success of tenofovir-containing
Fig. 2 Predicted phenotypic resistance (Stanford scores) for antiretroviral drugs currently recommended for first-line combination therapy in
the UK, 20102013. 3TC, lamivudine; ABC, abacavir; ATV, atazanavir; DRV, darunavir; EFV, efavirenz; FTC, emtricitabine; PI, protease inhibitor;
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; RPV, rilpivirine; TDF, tenofovir.
© 2016 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association. HIV Medicine (2016)
6 A Tostevin et al.
pre-exposure prophylaxis (PreP) if its use in the UK
becomes more widespread [30].
Our analysis found that region of treatment centre was a
significant predictor for the presence of TDRMs in the UK
population. Individuals referred for resistance tests from
treatment centres in Northern Ireland, Wales, the Midlands
and East England and the South of England were less likely
to have detectable TDRMs than those referred from London
centres. The cause of this is difficult to determine and will
be influenced by the extent to which transmission net-
works are regional or national. Recent work has shown that
a high proportion of drug-resistant HIV transmission in the
UK is from ART-na€ıve individuals [27,31]. It is possible,
therefore, that current geographical variation reflects his-
torical differences in the original emergence of resistant
strains, for example, as a result of earlier access to ART
drugs or the use of different ART in London. A related
explanation is that the average interval between HIV infec-
tion and onward transmission could be shorter in London
than in other parts of the UK, thereby increasing the chance
of onward transmission of resistant virus (rather than the
outgrowth of wild-type virus).
Table 4 Logistic regression model of risk factors for transmitted drug resistance mutations (TDRMs), 2010–2013
Patient characteristics Total TDRMs [n (%)] Univariate OR Multivariate OR 95% CI P-value
MSM
2010 1977 194 (9.8) Ref Ref – 0.06
2011 2022 183 (9.1) 0.91 0.90 0.73–1.11
2012 2057 166 (8.1) 0.81 0.79 0.63–0.98
2013 1477 111 (7.5) 0.75 0.73 0.56–0.94
Heterosexual male
2010 826 58 (7.0) Ref Ref – 0.51
2011 809 44 (5.4) 0.76 0.73 0.49–1.10
2012 618 38 (6.1) 0.87 0.83 0.54–1.27
2013 580 38 (6.6) 0.93 0.89 0.57–1.36
Heterosexual female
2010 1145 75 (6.6) Ref Ref – 0.86
2011 1018 68 (6.7) 1.02 1.00 0.71–1.41
2012 825 53 (6.4) 0.98 0.95 0.66–1.38
2013 647 38 (5.9) 0.89 0.85 0.56–1.28
Ethnicity
White 8169 682 (8.3) Ref Ref 0.16
Black African 3932 250 (6.4) 0.75 0.86 0.71–1.06
Black Caribbean 565 35 (6.2) 0.72 0.78 0.54–1.12
Asian 720 50 (6.9) 0.82 0.83 0.61–1.12
Other 1139 107 (9.4) 1.14 1.12 0.90–1.40
Age at diagnosis
15–24 years 1907 137 (7.2) 0.85 0.82 0.68–0.99 0.07
25–39 years 7232 603 (8.3) Ref Ref –
40–49 years 3307 234 (7.1) 0.84 0.86 0.73–1.00
≥50 years 1757 119 (6.8) 0.80 0.85 0.70–1.05
Region
London 7493 640 (8.5) Ref Ref – <0.01*
South England 2175 150 (6.9) 0.79 0.80 0.66–0.98
North England 2237 196 (8.8) 1.03 1.02 0.84–1.22
Midlands and East England 3208 165 (5.1) 0.58 0.60 0.49–0.73
Wales 441 20 (4.5) 0.51 0.51 0.32–0.81
Scotland 435 34 (7.8) 0.91 0.86 0.59–1.25
Northern Ireland 252 11 (4.4) 0.49 0.48 0.26–0.89
Baseline CD4 count
<200 cells/mL 3249 235 (7.2) 0.88 1.00 0.82–1.23 0.8
200–349 cells/mL 2508 178 (7.1) 0.86 0.91 0.74–1.12
350–499 cells/mL 2528 206 (8.1) Ref Ref –
≥500 cells/mL 3342 278 (8.3) 1.02 0.98 0.81–1.26
Baseline VL
<4.0 log10 copies/mL 1262 111 (8.8) 1.09 1.13 0.88–1.45 0.6
4.0 to <5.0 log10 copies/mL 2396 195 (8.1) Ref Ref –
≥5.0 log10 copies/mL 2268 185 (8.2) 1.00 1.02 0.82–1.26
RITA
Nonrecent 4864 358 (7.4) Ref – –
Recent 1098 94 (8.6) 1.18 – –
CI, confidence interval; MSM, men who have sex with men; OR, odds ratio; RITA, Recent Infection Testing Algorithm; VL, viral load.
*Injecting drug users and other transmission groups are included in the multivariate model but not presented here.
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The interpretation of time trends in TDRM prevalence
could be affected by temporal changes in the timing of
HIV diagnoses as there is evidence for earlier detection of
infections in more recent calendar years. We did not
observe an association between markers of recent infec-
tion, either high CD4 count or a low avidity index, and
prevalence of TDRMs. This might appear to be a surpris-
ing finding as resistant viruses in patients with long-
standing infection tend to be outcompeted by wild-type
viruses and cease to become detectable [26]. However,
this effect could be masked by changes in TDRM preva-
lence by year of infection. It is a limitation of our analy-
sis that baseline CD4 count was missing for 29% of
individuals. Baseline HIV-1 viral load measurements were
not available for a large proportion of individuals (64%),
making meaningful interpretation of these data difficult.
As integrase resistance testing is not currently recom-
mended in ART-na€ıve individuals in the UK, the number
of tests available to detect TDRMs conferring resistance
to integrase inhibitors was small and possibly selective.
No major resistance-conferring mutations were identified
in the 101 individuals analysed. However, with increasing
use of integrase inhibitors in the UK, and a move to use
them in first-line regimens, it seems important to monitor
TDR to this drug class [32]. Some form of sentinel
surveillance may be more cost-effective than universal
testing while the prevalence of TDRMs remains low.
In conclusion, our data demonstrate an overall
decrease in the prevalence of TDRMs in the UK, although
differences were evident between MSM and those living
with heterosexually acquired HIV infection. There
remains some risk of first-line therapy with efavirenz or
rilpivirine being compromised by the detected TDRMs,
but clinically relevant resistance to NRTIs, PIs and inte-
grase inhibitors is rarely seen. We recommend imple-
menting some sentinel surveillance, at selected treatment
centres, for TDRMs conferring resistance to integrase
inhibitors, given their increasing use as a first-line treat-
ment in the UK.
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Appendix : The UK HIV Drug Resistance
Database
Steering Committee: Celia Aitken (Gartnavel General
Hospital, Glasgow); David Asboe, Anton Pozniak (Chelsea
& Westminster Hospital, London); Patricia Cane (Public
Health England, Porton Down); David Chadwick (South
Tees Hospitals NHS Trust, Middlesbrough); Duncan
Churchill (Brighton and Sussex University Hospitals NHS
Trust); Duncan Clark (St Bartholomew’s and The London
NHS Trust); Simon Collins (HIV i-Base, London); Valerie
Delpech (Centre for Infections, Public Health England);
Samuel Douthwaite (Guy’s and St Thomas’ NHS Founda-
tion Trust, London); David Dunn, Esther Fearnhill, Kho-
loud Porter, Anna Tostevin, Ellen White (MRC Clinical
Trials Unit at UCL, London); Christophe Fraser (Imperial
College London); Anna Maria Geretti (Institute of Infec-
tion and Global Health, University of Liverpool); Antony
Hale (Leeds Teaching Hospitals NHS Trust); Stephane Hue
(London School of Hygiene and Tropical Medicine, Lon-
don); Steve Kaye (Imperial College, London); Paul Kellam
(Wellcome Trust Sanger Institute & University College
London Medical School); Linda Lazarus (Expert Advisory
Group on AIDS Secretariat, Public Health England);
Andrew Leigh-Brown (University of Edinburgh); Tamyo
Mbisa (Virus Reference Department, Public Health Eng-
land); Nicola Mackie (Imperial NHS Trust, London);
Samuel Moses (King’s College Hospital, London); Chloe
Orkin (St. Bartholomew’s Hospital, London); Eleni Nas-
touli, Deenan Pillay, Andrew Phillips, Caroline Sabin
(University College London Medical School, London);
Erasmus Smit (Public Health England, Birmingham Heart-
lands Hospital); Kate Templeton (Royal Infirmary of Edin-
burgh); Peter Tilston (Manchester Royal Infirmary); Ian
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Williams (Mortimer Market Centre, London); Hongyi
Zhang (Addenbrooke’s Hospital, Cambridge).
Coordinating Centre: MRC Clinical Trials Unit at UCL
(David Dunn, Keith Fairbrother, Esther Fearnhill, Kholoud
Porter, Anna Tostevin and Ellen White).
Centres contributing data: Clinical Microbiology and
Public Health Laboratory, Addenbrooke’s Hospital, Cam-
bridge (Jane Greatorex); Guy’s and St Thomas’ NHS
Foundation Trust, London (Siobhan O’Shea, Jane Mullen);
PHE – Public Health Laboratory, Birmingham Heartlands
Hospital, Birmingham (Erasmus Smit); PHE – Virus Refer-
ence Department, London (Tamyo Mbisa); Imperial Col-
lege Health NHS Trust, London (Alison Cox); King’s
College Hospital, London (Richard Tandy); Medical
Microbiology Laboratory, Leeds Teaching Hospitals NHS
Trust (Tracy Fawcett); Specialist Virology Centre,
Liverpool (Mark Hopkins, Lynne Ashton); Department of
Clinical Virology, Manchester Royal Infirmary, Manch-
ester (Peter Tilston); Department of Virology, Royal Free
Hospital, London (Clare Booth, Ana Garcia-Diaz); Edin-
burgh Specialist Virology Centre, Royal Infirmary of
Edinburgh (Jill Shepherd); Department of Infection &
Tropical Medicine, Royal Victoria Infirmary, Newcastle
(Matthias L. Schmid, Brendan Payne); South Tees Hospi-
tals NHS Trust, Middlesbrough (David Chadwick); Depart-
ment of Virology, St Bartholomew’s and The London
NHS Trust (Spiro Pereira, Jonathan Hubb); Molecular
Diagnostic Unit, Imperial College, London (Steve Kaye);
University College London Hospitals (Stuart Kirk); West
of Scotland Specialist Virology Laboratory, Gartnavel,
Glasgow (Rory Gunson, Amanda Bradley-Stewart, Celia
Aitken).
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